Table 1.
Baseline characteristics by subgroup
| Patients, N | Females, n (%) | Age, years | HbA1c, % | Duration of diabetes, years | Bodyweight, kg | BMI, kg/m2 | eGFR, mL/min/1.73 m2 | |
|---|---|---|---|---|---|---|---|---|
| PIONEER 9 | ||||||||
| Overall | 243 | 52 (21.4) | 59 (9) | 8.2 (0.9) | 7.6 (5.6) | 71.1 (13.3) | 25.9 (4.3) | 97 (12) |
| Baseline HbA1c, % | ||||||||
| ≤8.0 | 128 | 31 (24.2) | 59 (9) | 7.5 (0.3) | 7.0 (5.2) | 71.6 (13.8) | 26.3 (4.4) | 97 (12) |
| >8.0–≤9.0 | 68 | 10 (14.7) | 61 (9) | 8.5 (0.3) | 8.2 (5.8) | 69.7 (13.2) | 25.3 (4.2) | 95 (11) |
| >9.0 | 47 | 11 (23.4) | 59 (11) | 9.7 (0.5) | 8.3 (6.3) | 71.8 (12.4) | 25.5 (3.7) | 99 (12) |
| Baseline BMI, kg/m2 | ||||||||
| <25 | 108 | 23 (21.3) | 64 (8) | 8.3 (1.0) | 9.4 (5.9) | 61.4 (7.7) | 22.4 (1.7) | 94 (12) |
| ≥25–<30 | 100 | 16 (16.0) | 58 (9) | 8.2 (0.8) | 6.7 (5.3) | 74.8 (7.4) | 27.0 (1.3) | 98 (12) |
| ≥30 | 35 | 13 (37.1) | 52 (9) | 8.0 (1.0) | 4.5 (3.4) | 90.6 (13.6) | 33.5 (3.6) | 104 (11) |
| PIONEER 10 | ||||||||
| Overall | 458 | 117 (25.5) | 58 (10) | 8.3 (0.9) | 9.4 (6.3) | 72.1 (15.6) | 26.2 (4.8) | 97 (13) |
| Baseline HbA1c, % | ||||||||
| ≤8.0 | 206 | 53 (25.7) | 59 (10) | 7.5 (0.3) | 9.0 (6.7) | 72.1 (15.4) | 26.2 (4.4) | 95 (13) |
| >8.0–≤9.0 | 144 | 35 (24.3) | 58 (11) | 8.5 (0.3) | 9.4 (6.0) | 71.5 (14.9) | 26.0 (4.6) | 97 (14) |
| >9.0 | 108 | 29 (26.9) | 57 (10) | 9.7 (0.4) | 10.0 (5.9) | 73.0 (17.0) | 26.7 (5.7) | 99 (13) |
| Baseline BMI, kg/m2 | ||||||||
| <25 | 207 | 56 (27.1) | 62 (9) | 8.3 (0.9) | 11.1 (6.9) | 61.5 (8.3) | 22.7 (1.7) | 94 (13) |
| ≥25–<30 | 180 | 39 (21.7) | 57 (10) | 8.4 (0.9) | 8.1 (5.3) | 75.3 (9.1) | 27.2 (1.4) | 98 (14) |
| ≥30 | 71 | 22 (31.0) | 52 (10) | 8.4 (1.0) | 7.5 (5.4) | 94.8 (17.3) | 34.4 (5.3) | 103 (12) |
| Background medication | ||||||||
| SU | 147 | 27 (18.4) | 60 (10) | 8.5 (1.0) | 10.8 (6.8) | 70.2 (13.3) | 25.4 (4.1) | 96 (13) |
| Glinide | 77 | 21 (27.3) | 59 (10) | 8.4 (0.9) | 8.9 (5.3) | 71.2 (18.2) | 26.3 (6.3) | 95 (14) |
| TZD | 79 | 20 (25.3) | 60 (10) | 8.3 (0.9) | 8.8 (5.4) | 73.8 (13.6) | 27.2 (4.6) | 96 (12) |
| α‐GI | 77 | 28 (36.4) | 57 (11) | 8.2 (1.0) | 7.6 (6.6) | 72.8 (17.0) | 26.4 (4.4) | 97 (15) |
| SGLT2i | 78 | 21 (26.9) | 57 (10) | 8.2 (0.8) | 9.4 (6.3) | 74.3 (17.3) | 26.7 (4.8) | 99 (13) |
Data are the mean (SD) unless otherwise specified. Data are for all treatment arms combined for each subgroup in each trial. α‐GI, alpha‐glucosidase inhibitor; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; SD, standard deviation; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.